Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

NCT06967961 · tracked via the Priya Life Science France tracker

Sponsor

Institut Claudius Regaud

Phase

Not applicable

Started

2025-07-23

Last updated

2026-06-15

Condition(s) studied

Urothelial CarcinomaRenal CancerProstate AdenocarcinomaAdenocarcinoma of EndometriumCutaneous MelanomaSoft Tissue Sarcoma (STS)Nonseminomatous Germ Cell TumorSeminomatous Germ Cell TumorUpper Aerodigestive Tract CarcinomaCervical Carcinoma

Investigational drug(s) / intervention(s)

For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:: A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.

Study summary

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.

Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.

450 patients will be enrolled in total.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * 1\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors * 2\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet * 3\. Age ≥ 18 years * 4\. Patient affiliated to a French Social Security scheme * 5\. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study. Exclusion Criteria: * 1\. Patient with localized disease. * 2\. Pregnant or breast-feeding women. * 3\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol. * 4\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Primary outcome measure(s)

Rate of patients presenting blood circulating DP cells detected by at least one of the two tested techniques (Flow Cytometry/ CellSearch® or Parsortix® according to the type of tumor) — 1 year after the Last Patient Last Visit
It is defined as the ratio of number of patients for whom DP cells were detected (by at least 1 of the 2 techniques) by the total number of patients.

Trial sites (1)

Facility	City	Region	Status
Oncopole Claudius Regaud, IUCT-O	Toulouse	France	Recruiting

More Institut Claudius Regaud trials in France

Deciphering Mechanisms Underlying Cancer Immunogenicity Recruiting

Platino-resistance in Ovarian Cancer Recruiting

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy Recruiting

Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents Recruiting

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma Recruiting

Other trials for the same condition

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Active, not recruiting

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Active, not recruiting

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Active, not recruiting

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06967961 on ClinicalTrials.gov ↗ ← All trials in France